We are live on
!
Find out more
Fate Therapeutics
FATE
FATE
78 hedge funds and large institutions have $216M invested in Fate Therapeutics in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
475% more call options, than puts
Call options by funds: $46K | Put options by funds: $8K
115% more capital invested
Capital invested by funds: $101M → $216M (+$115M)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
7.39% more ownership
Funds ownership: 61.35% → 68.75% (+7.4%)
5% more funds holding
Funds holding: 74 → 78 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
78
Holders Change
+4
Holders Change %
+5.41%
% of All Funds
1.77%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
29
Reduced
19
Closed
13
Calls
$46K
Puts
$8K
Net Calls
+$38K
Net Calls Change
+$39K
Top Buyers
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$18.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 3 |
CC
Casdin Capital
New York
|
+$9.15M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.35M |
| 5 |
Millennium Management
New York
|
+$1.36M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.96M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.53M |
| 3 |
Goldman Sachs
New York
|
-$336K |
| 4 |
Renaissance Technologies
New York
|
-$333K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$318K |
